The International Parkinson and Movement Disorder Society (MDS) gathers thousands of the field's clinicians, researchers, trainees and industry supporters with an interest in the current research and approaches for the diagnosis and treatment of movement disorders on an annual basis at its International Congress of Parkinson's Disease and Movement Disorders®. The purpose of the MDS International Congress is to share ideas, encourage interest among all those involved in the care and research of movement disorders, to participate in the activities of MDS, and to advance the related clinical and scientific discipline.
The goal of the CTAD Asia -China Conference is to bring together Asian leaders on the treatment and management of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues that are essential to the development of the next generation of Alzheimer’s disease treatments.
This CTAD Asia - China Conference will focus largely on how to develop successful AD clinical trials worldwide through workshops on important topics for conducting clinical trials: methodology, database management of clinical trials, biomarkers, patient recruitment, etc.
The conference, now in its 11th year, features leading speakers from the healthcare and investment communities, who will provide insight into future trends in the healthcare industry.
The audience consists of senior management from private and public companies across Europe’s life-sciences sector, as well as a number of investors and analysts from the investment community.
CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Our mission is to have a positive impact on the success of clinical development programs. We believe this mission is our ethical duty to the patients we serve by developing new treatments.
The Huntington Study Group’s renowned annual event, HSG 2019: Navigating HD, will bring together more than 600 of the world’s leading Huntington disease (HD) researchers, health care providers, industry representatives, and members of the HD community to provide a forum for training and education in Huntington disease (HD) and for presentation of new research findings and treatments to the worldwide community,
The International Ataxia Research Conference will be a comprehensive scientific review of new research into ataxias, covering topics from the molecular basis of disease to potential therapeutic treatments and clinical trials. The conference will include Friedreich’s ataxia and other recessive ataxias (e.g. ataxia with oculomotor apraxia), dominant ataxias (e.g. spinocerebellar ataxias, DRPLA, episodic ataxias) and autoimmune ataxias. The meeting is aimed at academic, clinical and industry researchers with an interest in ataxia research and drug development.
The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
HAI 2020 will continue to emphasize ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily spring from brief presentations by active investigators who will report on unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.